531541 — KOBO Biotech Income Statement
0.000.00%
- IN₹70.52m
- IN₹1.46bn
- 13
- 12
- 52
- 11
Annual income statement for KOBO Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | — | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 84.9 | 78.4 | 151 | 55.7 | 49.4 |
| Operating Profit | -84.9 | -78.4 | -151 | -55.7 | -49.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -210 | -192 | -152 | -55.5 | -49.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -210 | -192 | -152 | -55.5 | -49.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -210 | -192 | -152 | -55.5 | -49.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -210 | -192 | -152 | -55.5 | -49.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.82 | -8.07 | -6.39 | -2.33 | -2.07 |